9880 Campus Point Drive STE 220
About Capstan Therapeutics
Capstan Therapeutics is developing a targeted delivery platform and therapeutics to reprogram immune cells in vivo in a scalable and controlled format, for a broad range of disease categories. The core technology originating from University of Pennsylvania comprises Targeted Lipid Nanoparticles (tLNPs) to enable off-the-shelf immunotherapies, with tight control of dosage and of activity of engineered cells. The objective is to advance transformative first-in-class and best-in-class products for oncology, fibrosis and inflammation-related diseases and blood monogenic disorders. Our dynamic start-up is founded by pioneers in the field of immunotherapy, regenerative medicine and drug delivery including experienced industry leaders and academic faculty members from U Penn.
In summary, Capstan Therapeutics aspires to become the leader of a new revolution in medicine, opening the avenue of in vivo reprogramming of the immune system and bringing this treatment modality to a broad range of medical needs. With locations in Philadelphia and San Diego, we are looking for talented individuals to join us.
11 articles about Capstan Therapeutics
Capstan Therapeutics to Present Preclinical Data at SITC Demonstrating Rapid Anti-Primary B Cell and Anti-Tumor Activity in Mice with Proprietary Targeted Lipid Nanoparticles Delivering an Anti-CD19 CAR mRNA Construct
Capstan Therapeutics, Inc. today announced it will present preclinical data showing rapid and robust anti-tumor and anti-primary B cell activity in humanized mice by tLNP administration delivering an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR), at the Society for Immunotherapy of Cancer 38th Annual Meeting in San Diego, California.
Capstan Therapeutics Co-Founder Drew Weissman, M.D., Ph.D., Awarded Nobel Prize in Physiology or Medicine for Enabling Rapid Development of RNA-based COVID-19 Vaccine
Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that the Company’s Co-Founder Drew Weissman, M.D., Ph.D., was awarded the 2023 Nobel Prize in Physiology or Medicine for his discoveries in nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.
Capstan Therapeutics, Inc. today announced that Capstan management will participate in the following upcoming industry conferences.
Capstan Therapeutics, Inc. today announced that Capstan management will participate in the following upcoming investor conferences.
Capstan Therapeutics Appoints Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D., as General Counsel
Capstan Therapeutics, Inc. today announced the appointment of Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D. as General Counsel.
Capstan Therapeutics, Inc. today announced that Capstan President and Chief Executive Officer, Laura Shawver, Ph.D., will participate in the upcoming Cowen 43rd Annual Health Care Conference, being held between March 6-8, 2023 at the Boston Marriott Copley Place in Boston, MA.
Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that Capstan management will participate in the upcoming SVB Securities 2023 Global Biopharma Conference, being held virtually between January 31-February 2 and February 13-16, 2023.
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
Capstan Therapeutics Announces Appointment of Athena Countouriotis, M.D., as Board Chair and Strengthens Leadership Team with Key Appointment
Capstan Therapeutics, Inc. announced the appointment of experienced biotechnology leader Athena Countouriotis, M.D., as Board Chair and Michael Rosenzweig, DVM, Ph.D., as Executive Vice President, Portfolio Strategy and Product Development.
Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering
Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering.
With $165 million in the bank, Capstan launched Wednesday to combine the potency of cell therapy with the precision of genetic medicines against various difficult-to-treat diseases.